Deep Brief — Medical Device User Fee Small Business Qualification & Determination (FDA guidance, July 31, 2025)

Open PDF

What it is, why it matters, and exactly what manufacturers — including regulatory, PV/PS (pharmacovigilance / product safety), quality and finance teams — must do

Short version: This FDA guidance explains how device and biologics firms can qualify as a “small business” for reduced MDUFA user fees (and for a one-time waiver of a first premarket fee or an establishment registration fee). The guidance sets the eligibility thresholds, the submission process (MDUFA SBR), timelines, special rules for foreign firms (National Taxing Authority certification), and practical steps firms must take to get fee relief. U.S. Food and Drug Administration

Below I turn the guidance into an actionable, work-ready article for regulatory affairs, finance, PV/product-safety, quality and leadership.

1) What this guidance covers (simple overview)

Defines three distinct small-business benefits and their gross-receipts thresholds:
- Reduced application fees (small business = gross receipts ≤ $100M).
- First premarket application/report fee waiver (small business = gross receipts ≤ $30M).
- Registration fee waiver (small business = gross receipts ≤ $1M and other conditions). U.S. Food and Drug Administration
Explains who must include affiliate revenues (affiliates’ receipts are aggregated).
Describes submission mechanics: use the MDUFA SBR (CDRH Portal), timelines for submission windows (SBRs accepted starting Aug 1 for the next FY, and other FY-specific windows), and the 60-day-before-fee-due evidence rule. U.S. Food and Drug Administration
Gives special instructions for foreign businesses (requires National Taxing Authority certification) and notes guidance differences for CDRH vs CBER regulated products. U.S. Food and Drug Administration

2) Why manufacturers should care — practical impact

Major cash savings and timing flexibility. User fees are material (often tens to hundreds of thousands USD); qualifying saves money and eases cashflow for premarket programs (510(k), De Novo, PMA/BLA, supplements). U.S. Food and Drug Administration
Program planning & portfolio decisions change. Reduced fees can shift the economics of pursuing certain regulatory pathways (e.g., pursuing a PMA vs incremental device changes). Expect changes in go/no-go thresholds.
Cross-functional implications: Regulatory must coordinate with Finance, Legal, Tax, and PV/Quality to assemble accurate affiliate revenue, confirm prior fee waivers, and certify financial hardship where required.
Foreign firms need government help. Non-US sponsors must obtain certs from their National Taxing Authority — a nontrivial, often slow administrative step that should be started early. U.S. Food and Drug Administration

3) Top 5 load-bearing facts from the guidance (cite these in communications)

$100M gross receipts threshold for reduced application fees. U.S. Food and Drug Administration
$30M threshold for the one-time “first premarket application/report fee waiver.” U.S. Food and Drug Administration
$1M threshold for registration fee waiver (plus prior registration/payment and evidence of hardship). U.S. Food and Drug Administration
SBR submission window begins Aug 1 for the coming fiscal year; plan early because approvals are FY-specific. U.S. Food and Drug Administration
Applicants must submit evidence at least 60 days before the fee is due. U.S. Food and Drug Administration

4) Real-world, role-by-role implications (what each team must do)

Regulatory Affairs (owner)

Lead the MDUFA SBR submission via the CDRH Portal.
Map each planned submission (PMA, 510(k), De Novo, BLA) to the FY and ensure SBR is approved before fee payment.
Maintain a calendar: SBR window opens Aug 1 for next FY; registration-waiver window (if applicable) runs through Oct 31 for active registrants. U.S. Food and Drug Administration

Finance / Tax (co-owner)

Calculate gross receipts for the most recent tax year inclusive of affiliates (consolidation rules are strict). Compile financial statements, tax returns, and affiliate proofs.
For foreign firms, engage the National Taxing Authority early — requests for certification can take weeks/months. U.S. Food and Drug Administration

Legal / Corporate (advisor)

Confirm affiliate relationships and legal definitions of “affiliate” for aggregation. Review prior waiver history (first premarket waiver is one-time).
Maintain documentary evidence of hardship if applying for registration fee waiver.

Quality / PV / Product Safety

While not primary authors of the SBR, PV/PS must factor into planning: if a product requires costly post-market studies or safety commitments, the fee savings may free budget for surveillance programs. Also: ensure registration fee waiver decisions don’t compromise postmarket reporting capabilities (i.e., don’t under-register critical establishments).
For biologics devices under CBER, coordinate with biologics safety teams to ensure labeling, REMS/PSUR timelines do not conflict with fee scheduling. U.S. Food and Drug Administration

Commercial & Portfolio Leads

Re-run net-present-value (NPV) models for projects after reduced fee scenarios; include timelines for when submissions can be filed for FY fee savings.

5) Immediate checklist (what to do in the next 30 days)

Run gross-receipts model (include affiliates). If receipts are near thresholds, run sensitivity analyses (e.g., what if an affiliate sale closes?).
Map submission calendar (which filings will require fees in next FY). Assign owners and target SBR submission date ≥60 days before fee due. U.S. Food and Drug Administration
For foreign entities: contact your National Taxing Authority now; request the MDUFA Foreign SBR certification process and expected timelines. U.S. Food and Drug Administration
Collect supporting documents: tax returns, audited financials, affiliate invoices, MOUs, and prior fee waiver records.
Update SOPs: create or revise an internal SOP for “Small Business Determination” so RFQ/tax/regs are coordinated each FY.

6) Common pitfalls & how to avoid them

Pitfall: forgetting to aggregate affiliate receipts → wrong determination.
Fix: use Legal + Finance to produce consolidated gross receipts and document chain of control. U.S. Food and Drug Administration
Pitfall: waiting until the last minute and missing the 60-day evidence window.
Fix: build SBR deadlines into the regulatory submission Gantt and set reminders for Aug 1 SBR open window.
Pitfall: foreign tax cert delays.
Fix: initiate National Taxing Authority engagement months ahead; consider local counsel or trade association help.

7) Example timeline (practical)

June–July: Finance compiles prior FY consolidated receipts & affiliate docs.
Aug 1: Submit MDUFA SBR for FY 2026 small business status (opens Aug 1). U.S. Food and Drug Administration
By Sept–Oct (≥60 days before fee due): FDA determination expected; schedule premarket submissions in FY window to use reduced fees.
Oct 31: Final window for registration fee waiver submissions for active registrants (if applicable). U.S. Food and Drug Administration

8) Draft language you can copy into internal memos

“Per FDA guidance (Medical Device User Fee Small Business Qualification and Determination, July 31, 2025), our team will compile consolidated gross receipts inclusive of affiliates and submit the MDUFA SBR for FY2026 when the portal opens on Aug 1. Regulatory and Finance will finalize documentation by July 25 to ensure the SBR is complete no later than July 31.” U.S. Food and Drug Administration

9) Longer-term strategy (why this affects PV and regulatory planning)

Budget reallocation: Fee savings can be redirected into more robust postmarket surveillance (registries, active safety studies) — important for products with near-term PMRs or REMS obligations.
Regulatory timing advantage: lower fees might encourage earlier filing of novel devices (De Novo/PMA), accelerating market entry. But coordinate with PV to ensure surveillance capacity scales with launch.
Compliance posture: completing SBRs on time and documenting affiliate calculations reduces audit risk during inspections or user-fee audits.

10) Useful annexes you should create now

Annex A: Template checklist for MDUFA SBR (documents required).
Annex B: SOP for “Small Business Determination” — owners, timeline, escalation path.
Annex C: Foreign Tax Authority contact list template & sample cover letter.
If you want, I’ll generate these templates now in Word/PDF.

Sources

FDA — Medical Device User Fee Small Business Qualification and Determination; Guidance for Industry, FDA Staff and Foreign Governments (Document issued July 31, 2025). U.S. Food and Drug Administration

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.